EirGenix, in partnership with Sandoz, announced positive safety and efficacy results for its trastuzumab biosimilar in patients with breast cancer.
Phase 3 clinical trial results confirmed that a trastuzumab biosimilar candidate (EG12014) developed by EirGenix is biosimilar to the reference product (Herceptin), the company said in a statement.
EirGenix, based in Taipei, Taiwan, said it will move forward with plans to submit marketing approval applications to the FDA, the European Medicines Agency, and the Taiwan FDA.
If EG12014 is approved, Sandoz will be in charge of global marketing in the United States and European Union, but not in Taiwan and Mainland China, according to a licensing agreement between Sandoz and EirGenix signed in April 2019.
In 2020, global sales for Herceptin, facing heavy biosimilar competition in Europe, the United States, and elsewhere, dropped 34% from 2019, according to Roche’s annual report. Overall, biosimilar competition eroded $6.34 billion of the company’s international revenues for 2020 and Roche anticipates losing another $5.1 billion to biosimilars in 2021.
The trastuzumab biosimilar candidate, if it is priced below reference, may be well received in Taiwan given that Taiwan’s National Health Insurance paid $57.9 million for Herceptin therapy in 2019.
The phase 3 trial was a multinational, multicenter, randomized, double-blinded study that enrolled 807 women with human epidermal growth factor receptor 2 (HER2)–positive breast cancer. Patients were randomly assigned 1:1 to two treatment groups and were administered anthracycline-based chemotherapy every 3 weeks for 12 weeks.
After receiving chemotherapy, patients were given either EG12014 or the reference drug in combination with paclitaxel once every 3 weeks for 12 weeks. All patients had tumor removal surgery scheduled to take place 3 to 6 weeks after completing neoadjuvant therapy.
During the surgery, investigators collected samples to assess the pathologic complete response (pCR), which was conducted by an independent central laboratory. The study’s primary endpoint of pCR was defined as no invasive cancer in the breast and axillary nodes.
Results of the study demonstrated that EG12014 was bioequivalent to the reference product in terms of clinical response, and the safety profiles between the two were comparable in the preoperative treatment setting.
The trial results come after results from a different study, presented at the National Comprehensive Cancer Network (NCCN) Virtual Annual Conference 2021, showed high early adoption rates for Amgen’s trastuzumab biosimilar, which launched on the US market in July 2019.
Reference
Positive phase III clinical results for EirGenix's proposed trastuzumab biosimilar. News release. EirGenix. March 24, 2021. Accessed March 25, 2021. http://www.eirgenix.com/en/news/show.aspx?num=168
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.